Format
Sort by
Items per page

Send to

Choose Destination

Best matches for electrical shock AND ("QT" OR Torsad*):

Search results

Items: 1 to 20 of 34

1.

Electrical storm in an infant with short-coupled variant of torsade de pointes.

Kise H, Ohno S, Kono Y, Yoshizawa M, Harama D, Okafuji A, Toda T, Koizumi K, Hoshiai M, Sugita K, Horie M.

J Arrhythm. 2018 May 14;34(3):315-318. doi: 10.1002/joa3.12071. eCollection 2018 Jun.

2.

Use of the Wearable Cardioverter Defibrillator in High-Risk Populations.

Lamichhane M, Safadi A, Surapaneni P, Salehi N, Thakur RK.

Curr Cardiol Rep. 2016 Aug;18(8):78. doi: 10.1007/s11886-016-0746-5. Review.

PMID:
27319008
3.

Subcutaneous defibrillator implantation in pediatric patients.

Ertuğrul İ, Karagöz T, Aykan H, Yıldırım I, Özer S, Karagöz H, Yılmaz M.

Anatol J Cardiol. 2016 Aug;16(8):630-634. doi: 10.5152/AnatolJCardiol.2015.6589. Epub 2015 Nov 18.

4.

Heat shock protein 70 gene polymorphisms' influence on the electrophysiology of long QT syndrome.

Ali A, Qureshi SF, Medikare V, Venkateshwari A, Calambur N, Rao H, Jayakrishnan MP, Shenthar J, Thangaraj K, Nallari P.

J Interv Card Electrophysiol. 2016 Mar;45(2):119-30. doi: 10.1007/s10840-015-0082-5. Epub 2015 Dec 16.

PMID:
26670457
5.

High Glucose Represses hERG K+ Channel Expression through Trafficking Inhibition.

Shi YQ, Yan M, Liu LR, Zhang X, Wang X, Geng HZ, Zhao X, Li BX.

Cell Physiol Biochem. 2015;37(1):284-96. doi: 10.1159/000430353. Epub 2015 Aug 24.

6.

hERG potassium channel blockade by the HCN channel inhibitor bradycardic agent ivabradine.

Melgari D, Brack KE, Zhang C, Zhang Y, El Harchi A, Mitcheson JS, Dempsey CE, Ng GA, Hancox JC.

J Am Heart Assoc. 2015 Apr 24;4(4). pii: e001813. doi: 10.1161/JAHA.115.001813.

7.

KCNE2 modulates cardiac L-type Ca(2+) channel.

Liu W, Deng J, Wang G, Zhang C, Luo X, Yan D, Su Q, Liu J.

J Mol Cell Cardiol. 2014 Jul;72:208-18. doi: 10.1016/j.yjmcc.2014.03.013. Epub 2014 Mar 26.

PMID:
24681347
8.

Subcutaneous implantable defibrillator: State-of-the art 2013.

Akerström F, Arias MA, Pachón M, Puchol A, Jiménez-López J.

World J Cardiol. 2013 Sep 26;5(9):347-54. doi: 10.4330/wjc.v5.i9.347. Review.

9.

[A case of electrical storm in a patient with short-coupled variant of torsade de pointes].

Conte G, Coppini L, Demola MA, Ardissino D.

G Ital Cardiol (Rome). 2013 Jan;14(1):76-8. doi: 10.1714/1207.13375. Italian.

PMID:
23258207
10.

Vernakalant. Too dangerous in atrial fibrillation.

[No authors listed]

Prescrire Int. 2012 May;21(127):119-22. Review.

PMID:
22827000
11.

Management of unstable arrhythmias in cardiogenic shock.

Saidi A, Akoum N, Bader F.

Curr Treat Options Cardiovasc Med. 2011 Aug;13(4):354-60. doi: 10.1007/s11936-011-0132-y.

PMID:
21626366
12.

Prevalence and persistence of depression in patients with implantable cardioverter defibrillator: a 2-year longitudinal study.

Suzuki T, Shiga T, Kuwahara K, Kobayashi S, Suzuki S, Nishimura K, Suzuki A, Ejima K, Manaka T, Shoda M, Ishigooka J, Kasanuki H, Hagiwara N.

Pacing Clin Electrophysiol. 2010 Dec;33(12):1455-61. doi: 10.1111/j.1540-8159.2010.02887.x. Epub 2010 Oct 14.

PMID:
20946285
13.

Low hemoglobin levels during normovolemia are associated with electrocardiographic changes in pigs.

Scheller B, Pipa G, Kertscho H, Lauscher P, Ehrlich J, Habler O, Zacharowski K, Meier J.

Shock. 2011 Apr;35(4):375-81. doi: 10.1097/SHK.0b013e3181f6aa44.

PMID:
20856175
14.

Nifekalant versus lidocaine for in-hospital shock-resistant ventricular fibrillation or tachycardia.

Shiga T, Tanaka K, Kato R, Amino M, Matsudo Y, Honda T, Sagara K, Takahashi A, Katoh T, Urashima M, Ogawa S, Takano T, Kasanuki H; Refractory VT/VF, Prospective Evaluation to Differentiate Lidocaine Efficacy from Nifekalant (RELIEF) Study Investigators.

Resuscitation. 2010 Jan;81(1):47-52. doi: 10.1016/j.resuscitation.2009.09.027. Epub 2009 Nov 13.

PMID:
19913983
15.

Effects of verapamil on anterior ST segment and ventricular fibrillation cycle length in patients with Brugada syndrome.

Chinushi M, Iijima K, Tagawa M, Komura S, Furushima H, Aizawa Y.

J Electrocardiol. 2009 Jul-Aug;42(4):367-73. doi: 10.1016/j.jelectrocard.2009.03.009. Epub 2009 Apr 7.

PMID:
19356768
16.

The effects of nifekalant hydrochloride on the QT dispersion after direct-current defibrillation.

Maeda K, Takagi M, Tatsumi H, Nakagawa E, Yoshiyama M.

Osaka City Med J. 2008 Jun;54(1):11-9.

PMID:
18819261
17.

Effect of nifekalant for acute conversion of atrial flutter: the possible termination mechanism of typical atrial flutter.

Morita N, Tanaka K, Yodogawa K, Hayashi M, Akutsu K, Yamamoto T, Satoh N, Kobayashi Y, Katoh T, Takano T.

Pacing Clin Electrophysiol. 2007 Oct;30(10):1242-53.

PMID:
17897127
18.

QT dispersion significantly increases after implantable cardioverter-defibrillator shocks.

Topaloglu S, Aras D, Sahin O, Ergun K, Deveci B, Ozdemir O, Ozeke O, Yildiz A, Alyan O, Demir AD, Soylu M, Kisacik HL, Korkmaz S.

Ann Noninvasive Electrocardiol. 2007 Jan;12(1):44-9.

PMID:
17286650
19.

[Characterization of premature ventricular contraction initiating ventricular fibrillation].

Sacher F, Victor J, Hocini M, Maury P, Jais P, Boveda S, Lamaison D, Cauchemez B, Pasquié JL, Frank R, Haïssaguerre M, Clementy J.

Arch Mal Coeur Vaiss. 2005 Sep;98(9):867-73. French.

PMID:
16231572
20.

Short QT syndrome.

Schimpf R, Wolpert C, Gaita F, Giustetto C, Borggrefe M.

Cardiovasc Res. 2005 Aug 15;67(3):357-66. Review.

PMID:
15890322

Supplemental Content

Loading ...
Support Center